Skip to main content
. 2019 Feb 4;7:30. doi: 10.1186/s40425-019-0508-1

Fig. 2.

Fig. 2

Kaplan–Meier estimates of progression-free survival (PFS) and overall survival (OS). a PFS from start of avelumab in the first-line switch-maintenance (1 L-mn) subgroup (n = 90). b OS from start of avelumab in the 1 L-mn subgroup (n = 90). c OS from start of 1 L chemotherapy in the 1 L-mn subgroup (n = 90). d PFS in the second-line (2 L) subgroup (n = 60). e OS in the 2 L subgroup (n = 60)